# Basepaws: A Petcare Genetics Company
High-Level Overview
Basepaws is a petcare genetics company, not a traditional technology company, though it leverages advanced biotechnology and computational tools. Founded in 2017 by Anna Skaya, Basepaws builds early-detection health risk tests based on genetic and microbiome data for companion animals.[1][3] The company serves pet owners and veterinarians seeking proactive health management for their pets, solving the problem of undetected genetic predispositions and oral health risks in cats and dogs.
Basepaws was acquired by Zoetis Inc. (NYSE:ZTS), a global animal health leader, in June 2022, which significantly expanded its reach and resources.[1] The company has demonstrated strong growth momentum, with sample volumes doubling or tripling annually over a four-year period.[2] Its product portfolio includes the Breed + Health DNA Test for dogs (retailing at $149, with introductory pricing at $85) and comprehensive genetic testing for cats, leveraging whole genome sequencing technology.[3]
Core Differentiators
- Next-Generation Sequencing (NGS) Technology: Basepaws is the first company in pet genetics to employ Illumina's NGS technology, conducting in-house whole genome sequencing and delivering data on approximately 2.5 billion nucleotide bases per genome.[3]
- Comprehensive Health Markers: The platform analyzes over 45 health markers for cats and 280+ for dogs, covering seven disease focus areas including oral health, renal disease, gastrointestinal disease, cancer, and longevity.[4]
- Proprietary Genomic Database: Basepaws has built the world's largest feline genomics database containing tens of thousands of cat genomes, continuously expanded through a citizen science community model.[2][4]
- Rapid Turnaround & Cost Efficiency: Using Illumina's DRAGEN platform on Amazon Web Services, Basepaws reduced computational time by approximately 50% and report delivery from 2-3 days to less than one day.[2]
- Oral Microbiome Analysis: Beyond genetic testing, Basepaws uniquely quantifies microbial species in the oral cavity and calculates disease risk scores for dental health.[6]
Role in the Broader Tech Landscape
Basepaws operates at the intersection of precision medicine, consumer genomics, and pet wellness—a rapidly expanding market segment. The company benefits from declining sequencing costs and increased accessibility of NGS technology, which became economically viable for consumer pet testing around 2018.[2] As pet owners increasingly view their animals as family members deserving preventive healthcare, Basepaws addresses a growing demand for data-driven pet wellness tools.
The company's integration into Zoetis's portfolio positions it within the broader animal health innovation ecosystem, where genetic insights inform veterinary decision-making and pharmaceutical development. Basepaws' citizen science model—where pet parents contribute health data and samples—creates a virtuous cycle of research that strengthens its competitive moat while building community engagement.
Quick Take & Future Outlook
Basepaws is well-positioned to become the dominant player in companion animal genomics. Under Zoetis's ownership, the company gains distribution channels, regulatory expertise, and capital to scale internationally. The expansion from cats to dogs signals a multi-species strategy, and the focus on early disease detection aligns with the broader healthcare trend toward preventive care.
The company's future likely involves deeper integration with veterinary practices, expansion into additional species, and development of more specialized health screening tools informed by its growing genomic database. As pet healthcare spending continues to rise and genetic testing becomes normalized, Basepaws' combination of scientific rigor, technological sophistication, and consumer accessibility positions it as a foundational player in the emerging precision pet health market.
